News
Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications
Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) , a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and
Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the fourth quarter and year ended December 31, 2019. Amounts, unless
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, 2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and full year 2019 financial results on Thursday, March 5, 2020, after
Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that Mr. Peter Greenleaf, President and Chief Executive Officer, will present a corporate overview at the 9th
Canopy Growth: Das war der Befreiungsschlag!
Wie ein zu Barrons gehörendes bedeutendes Online-Finanzportal berichtet, würden die Anleger billiges Marihuana bevorzugen. Canopy Growth (WKN: A140QA) sei dabei derjenige Branchenplayer, der im
Canopy Growth: Was Aurora kann...
...kann Canopy Growth (WKN: A140QA) schon lange. Nein, Canopy kann es sogar viel besser. Der Cannabis-Marktführer meldet heute Quartalszahlen, die im Gegensatz zu den Horrorzahlen von Aurora
Cannabis-Roundup: Canopy Growth & Aurora Cannabis
Investoren strömen wieder in den Sektor. In den letzten Tagen konnten die Aktien von Canopy Growth (WKN: A140QA), Aurora Cannabis (WKN: A12GS7) oder Tilray (WKN: A2JQSC) stark hinzugewinnen.
Das
LION E-Mobility: Nach dem Deal ist vor der Rallye?
LION E-Mobility (WKN: A140QA) hatte mit der kanadischen Firma "The Lion Electric Co." vor Weihnachten einen „Multimillionen-Serienliefervertrag über BMW-Batterien“ geschlossen. Nun gibt das
LION E-Mobility: Serienliefervertrag für E-Schulbusse fix
LION E-Mobility (WKN: A140QA) wird Serienlieferant von Batterien für E-Schulbusse und E-LKWs. Dazu schloss das Unternehmen einen „potentiellen Multimillionen-Serienliefervertrag über BMW-Batterien“.
Canopy Growth: Wie gewonnen, so zerronnen?
Zeitgleich mit Wechsel des Finanzchefs vom "Corona"-Brauer Constellation Brands an die Spitze von Canopy Growth (WKN: A140QA) scheint das Vertrauen in die grüne Wachstumsbranche zurückgekehrt (wir b
Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
Aurinia Prices US$166.7 Million Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
Aurinia Announces Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and
Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and
Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
Aurinia Announces Updates to the Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory
Canopy Growth: Die Spekulationsblase im Cannabis-Sektor ist geplatzt!
Es ist noch gar nicht so lange her, da rissen sich die Anleger um alle Aktien, die nur im entferntesten Sinne etwas mit Cannabis zu tun hatten. Denn schließlich sollte Cannabis ja plötzlich nahezu
Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its third quarter 2019 financial results on Thursday, November 14, 2019, after the market
Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and
Is Aurinia Pharmaceuticals a Buy?
Where Will Aurinia Pharmaceuticals Be in 5 Years?
3 Charts That Show Why Aurinia Pharmaceuticals Stock Could Go Higher